JP2022510304A5 - - Google Patents

Info

Publication number
JP2022510304A5
JP2022510304A5 JP2021531035A JP2021531035A JP2022510304A5 JP 2022510304 A5 JP2022510304 A5 JP 2022510304A5 JP 2021531035 A JP2021531035 A JP 2021531035A JP 2021531035 A JP2021531035 A JP 2021531035A JP 2022510304 A5 JP2022510304 A5 JP 2022510304A5
Authority
JP
Japan
Prior art keywords
peg
solid solution
capsule formulation
nonionic surfactant
solution capsule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021531035A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022510304A (ja
JP7342124B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/063547 external-priority patent/WO2020112961A1/en
Publication of JP2022510304A publication Critical patent/JP2022510304A/ja
Publication of JP2022510304A5 publication Critical patent/JP2022510304A5/ja
Application granted granted Critical
Publication of JP7342124B2 publication Critical patent/JP7342124B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021531035A 2018-11-30 2019-11-27 カプセル製剤 Active JP7342124B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862773848P 2018-11-30 2018-11-30
US62/773,848 2018-11-30
PCT/US2019/063547 WO2020112961A1 (en) 2018-11-30 2019-11-27 Capsule formulations

Publications (3)

Publication Number Publication Date
JP2022510304A JP2022510304A (ja) 2022-01-26
JP2022510304A5 true JP2022510304A5 (https=) 2023-03-15
JP7342124B2 JP7342124B2 (ja) 2023-09-11

Family

ID=70849818

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021531035A Active JP7342124B2 (ja) 2018-11-30 2019-11-27 カプセル製剤

Country Status (31)

Country Link
US (4) US20200170957A1 (https=)
EP (3) EP4487915A3 (https=)
JP (1) JP7342124B2 (https=)
KR (1) KR102586747B1 (https=)
CN (1) CN113164403A (https=)
AR (1) AR117219A1 (https=)
AU (1) AU2019389031B2 (https=)
BR (1) BR112021010285A2 (https=)
CA (1) CA3120999C (https=)
CL (1) CL2021001389A1 (https=)
CY (1) CY1126079T1 (https=)
DK (2) DK3886820T3 (https=)
ES (2) ES2998858T3 (https=)
FI (2) FI3886820T3 (https=)
HR (2) HRP20230551T1 (https=)
HU (2) HUE069633T2 (https=)
IL (1) IL283450B2 (https=)
LT (2) LT4233850T (https=)
MA (2) MA54318B1 (https=)
MD (2) MD3886820T2 (https=)
MX (1) MX2021006242A (https=)
NZ (1) NZ776554A (https=)
PL (2) PL4233850T3 (https=)
PT (2) PT4233850T (https=)
RS (2) RS64250B1 (https=)
SG (1) SG11202105572UA (https=)
SI (2) SI4233850T1 (https=)
SM (2) SMT202400521T1 (https=)
TW (1) TWI827745B (https=)
WO (1) WO2020112961A1 (https=)
ZA (1) ZA202103820B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020112961A1 (en) 2018-11-30 2020-06-04 Chemocentryx, Inc. Capsule formulations
US11603356B2 (en) 2019-11-08 2023-03-14 Chemocentryx, Inc. Amorphous form of a complement component C5a receptor
CN116529241A (zh) * 2020-10-28 2023-08-01 坎莫森特里克斯公司 治疗化脓性汗腺炎的方法
JP7839157B2 (ja) * 2020-10-28 2026-04-01 ケモセントリックス， インコーポレイテッド 化膿性汗腺炎を処置する方法
WO2022140258A1 (en) * 2020-12-21 2022-06-30 Chemocentryx, Inc. Treatment of c3 glomerulopathy using a c5a inhibitor
CN119031903A (zh) * 2022-05-19 2024-11-26 陶氏环球技术有限责任公司 基于peg的聚合物间复合物用于改善bcs ii类药物的增溶的用途
WO2025203055A1 (en) * 2024-03-26 2025-10-02 Council Of Scientific And Industrial Research Encapsulated dihydrofolate formulation for dietary supplementation as effective nutraceutical supplement and method of preparation thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR038681A1 (es) * 2002-02-14 2005-01-26 Solvay Pharm Bv Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua
BRPI0518484A2 (pt) 2004-11-24 2008-11-18 Merck & Co Inc composiÇço, cÁpsula, e, processo para preparar a mesma
DE102005053066A1 (de) 2005-11-04 2007-05-10 Basf Ag Verwendung von Copolymeren als Solubilisatoren für in Wasser schwerlöslichen Verbindungen
CA2689137C (en) * 2007-05-29 2017-05-02 Intrexon Corporation Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
RS54998B1 (sr) 2008-12-22 2016-11-30 Chemocentryx Inc Antagonisti c5ar
NZ602288A (en) * 2010-03-10 2014-02-28 Abbvie Bahamas Ltd Solid compositions comprising amorphous (2r,6s,13as,14ar,16as,z)-n-(cyclopropylsulfonyl)-6-(5-methylpyrazine-2-carboxamido)-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a-carboxamide
RS56332B1 (sr) * 2010-06-24 2017-12-29 Chemocentryx Inc Antagonisti c5ar
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9074470B2 (en) 2010-12-27 2015-07-07 Seven Generations Energy Ltd. Methods for drilling and stimulating subterranean formations for recovering hydrocarbon and natural gas resources
WO2015118015A1 (en) 2014-02-05 2015-08-13 Lek Pharmaceuticals D.D. Solid pharmaceutical compositions of androgen receptor antagonists
DK3200791T3 (da) 2014-09-29 2020-05-25 Chemocentryx Inc Fremgangsmåder og mellemprodukter i fremstilling af C5AR- antagonister
JP7339733B2 (ja) 2016-01-14 2023-09-06 ケモセントリックス，インコーポレイティド Ｃ３腎症を処置する方法
EP3439658B1 (en) 2016-04-04 2021-11-24 ChemoCentryx, Inc. Soluble c5ar antagonists
TWI826364B (zh) 2017-04-03 2023-12-21 德商因夫萊亞斯有限公司 活性抑制劑於發炎性疾病之治療
CA3077395A1 (en) 2017-10-30 2019-05-09 Chemocentryx, Inc. Deuterated compounds as immunomodulators
CA3078732A1 (en) 2017-10-31 2019-05-09 Chemocentryx, Inc. C5ar inhibitor reduction of urinary scd163
US11191756B2 (en) 2018-06-07 2021-12-07 Chemocentryx, Inc. Dosing and effect of C5a antagonist with ANCA-associated vasculitis
WO2020112961A1 (en) 2018-11-30 2020-06-04 Chemocentryx, Inc. Capsule formulations

Similar Documents

Publication Publication Date Title
JP2022510304A5 (https=)
IL283450B1 (en) Solid solution capsule formulations containing (3S,2R)-2-(4-(cyclopentylamino)phenyl)-1-(2-fluoro-6-methylbenzoyl)-N-(4-methyl-3-(trifluoromethyl)phenyl) Piperidine-3-carboxamide, methods for their preparation and their medical uses
JP7577069B2 (ja) 嚢胞性線維症膜貫通コンダクタンス制御因子調節剤
JP5684192B2 (ja) トリアゾロ［４，５−ｄ］ピリミジン化合物の新規な結晶形及び非晶形
JP2000503665A (ja) ミコフェノレートの腸溶性コーティング医薬組成物
CA3068609A1 (en) Compositions and methods for treatment of cystic fibrosis
US9796685B2 (en) Formulations of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-Methylcyclohexylamino)-pyrimidine-5-carboxamide
JPH0696524B2 (ja) バルプロ酸をベ−スとした新規薬剤組成物及びその製法
CN105338982B (zh) 固体药用组合物
TW200815360A (en) Novel compounds
KR20180086497A (ko) sGC 자극제를 포함하는 고체 분산물
JP2005516009A (ja) 重水素化された置換ピラゾリル−ベンゼンスルホンアミド並びにこれを含有する医薬品
JP2023501789A5 (https=)
CN114206842A (zh) 盐
TW201720444A (zh) 含有2-{4-[n-(5,6-二苯基吡 -2-基)-n-異丙基胺基]丁基氧基}-n-(甲基磺醯基)乙醯胺之醫藥組合物
CN109153735A (zh) 基于环糊精的聚合物、其方法、组合物和应用
TW201006819A (en) Pharmaceutical formulation comprising a CB1-receptor compound in a solid solution and/or solid dispersion
TWI358407B (en) Crystalline base of escitalopram and orodispersibl
RU2021118878A (ru) Лекарственные формы в виде капсул
CN111263754A (zh) 结晶
JP2003510267A (ja) 医薬担体処方
EP4084792A1 (en) Penicillin derivatives and method for their synthesis
TWI859242B (zh) 嘧啶基胺基-吡唑化合物之修飾釋放調配物及治療方法
JP5888612B2 (ja) 縮合ピリジン化合物塩の結晶
TWI753952B (zh) 治療阿茲海默氏病及帕金森氏病之組合物及方法